Clareo Health | Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test
Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
With
Pfizer
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female ambulatory outpatients being seen in a participating physicians office for routine care,
Patients with a clinical diagnosis of COPD (all stages according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2010) being treated with long-acting anticholinergic (Tiotropium, Spiriva® HandiHaler® ) as maintenance therapy within the product label and a maximum of the last 4 weeks (0.-28. days before Visit 1),
Patients previously treated with short-acting bronchodilators on regular or as-needed basis for at least 3 months before change to long-acting anticholinergic treatment,
Patient fluent in language of questionnaire and having the cognitive and functional abilities required to fill in the questionnaire alone.
You may not be if
Uncooperative patients as judged by the physician,
Patients with any conditions excluded as per Country specific package insert,
Patients currently enrolled in any clinical trial,
Patients with COPD exacerbation or any acute disease in the last 3 months before Visit 1.
